New anticoagulants

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 8, 2005, Pages 1843-1853

  Bates, S M ^a   Weitz, Jeffrey I ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON RESEARCH CENTRE   (Canada)

Author keywords

Anticoagulant; Antithrombotic; Arterial thromboembolism; Direct thrombin inhibitor; Pentasaccharide; Venous thromboembolism

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; ANTICOAGULANT PROTEIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A INHIBITOR; BLOOD CLOTTING FACTOR 9A INHIBITOR; BMS 562247; DABIGATRAN ETEXILATE; DU 176B; ENOXAPARIN; FONDAPARINUX; HEPARIN DERIVATIVE; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; LY 51; LY 51 7717; MELAGATRAN; PENTASACCHARIDE; PLACEBO; PROTEIN NAPC2; RAZAXABAN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; ARTERY THROMBOSIS; BLOOD CLOTTING; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; ISCHEMIA; KIDNEY CLEARANCE; PRIORITY JOURNAL; PROPHYLAXIS; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; AZETIDINES; BENZIMIDAZOLES; BENZYLAMINES; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; FACTOR IX; FIBRINOLYTIC AGENTS; HUMANS; MODELS, BIOLOGICAL; PROTEIN C; PYRIDINES; THROMBIN; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 28344452424     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01374.x     Document Type: Conference Paper

References (116)

1. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.
2. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of deep venous thrombosis. A meta-analysis of randomized controlled trials. Ann Intern Med 1999; 130: 800-9.
3. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999; 130: 789-99.
4. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004; 140: 175-83.
5. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndromes without ST-elevation: a meta-analysis. Lancet 2000; 355: 1936-42.
6. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-75.
7. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-98.
8. Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P, Schaub RG, Wagner DD, Kumar A, Wakefield TW. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 2003; 38: 1075-89.
9. Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, Sajer SA, Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-51.
10. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 75: 1-6.
11. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor Jr FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-6.
12. Elsayed YA, Nalagawa K, Kamikubo YI, Enjyoji KI, Kato H, Sueishi K. Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model. Am J Clin Pathol 1996; 106: 574-83.
13. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997; 78: 471-7.
14. Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, Zwingelstein C, Percell S, Shu V, Leighton A, Creasey AA. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29: 8081-9.
15. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, DeDeyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA, Optimist Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290: 238-47.
16. Stassens P, Bergum PW, Gansemans Y, Jespers L, LaRoche Y, Huang S, Maki S, Messens J, Lauwereys M, Cappello M, Hotez PJ, Lasters I, Vlasuk GD. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci USA 1996; 93: 2149-54.
17. Lee A, Agnelli G, Buller H, Ginsberg J, Heit J, Rote W, Vlasuk G, Costantini L, Julian J, Comp P, Van Der Meer J, Piovetta F, Raskob G, Gent M. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104: 74-78.
18. Banner DW, D'Arcy A, Chene C, Winkler F, Guha A, Konigsberg WH, Nemerson Y, Kirchhofev D. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380: 41-46.
19. Harker LA, Hanson SR, Kelly AB. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost 1997; 78: 736-41.
20. Arnljots B, Ezban M, Hedner U. Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa. J Vasc Surg 1997; 25: 341-6.
21. Golino P, Ragni M, Cirillo P, D'Andrea D, Scognamiglio A, Ravera A, Buono C, Ezban M, Corcione N, Vigorito F, Condorelli M, Chiarello M. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent and arterial thrombosis. Circulation Res 1998; 82: 39-46.
22. Jang Y, Guzman LA, Lincoff AM, Gottwauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92: 3041-50.
23. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
24. Lincoff AM. First clinical investigation of a tissue-factor inhibitor administered during percutaneous coronary revascularization: a randomized, double-blinded, dose-escalation trial assessing safety and efficacy of FFR-FVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial. JACC 2000; 36: 312 (Abstract).
25. Hoffman M, Monroe DM, Oliver JA, Roberts HR. Factors IXa and Xa play distinct roles in tissue-dependent initiation of coagulation. Blood 1995; 86: 1794-801.
26. Benedict CR, Ryan J, Wolitzky B, Ramos R, Gerlach M, Tijburg P, Stern D. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest 1991; 88: 1760-5.
27. Bajaj SP, Rapaport SI, Maki SL. A monoclonal antibody to factor IX that inhibits the factor VII:Ca potentiation of factor X activation. J Biol Chem 1985; 260: 11574-80.
28. Feuerstein GZ, Patel A, Toomey JR, Bugelski P, Nichols AJ, Church WR, Valocik R, Koster P, Baker A, Blackburn MN. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Arterioscler Thromb Vasc Biol 1999; 19: 2554-62.
29. Feurerstein GZ, Toomey JR, Valocik R, Koster P, Patel A, Blackburn MN. An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis. Thromb Haemost 1999; 92: 1443-50.
30. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JB. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin invest 1993; 191: 1877-83.
31. Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by heparin-antithrombin complex. Blood 2001; 97: 2308-13.
32. Brufatto N, Nesheim ME. The use of prothrombin (S525C) labelled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation. J Biol Chem 2001; 276: 17663-71.
33. Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Invest Drugs 2002; 11: 397-404.
34. Herbert JM, Herault JP, Bernat A, Van Amsterdam RG, Lormeau JC, Petitou M, Vanboeckel C, Hoffman P, Meuleman DG. Biochemical and pharmacological properties of SANORG 340006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91: 4197-205.
35. Boneu B, Necciari J, Cariou R, Sie P, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107A/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74: 1468-73.
36. Walenga J, Jeske W, Bara L, Samama MM, Fareed J. Biochemical and pharmacological rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86: 1-36.
37. Lagrange F, Vergnes C, Brun JL, Paolucci F, Nadal T, Leng JJ, Saux MC, Banwarth B. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemos 2002; 87: 831-5.
38. Dempfle CH. Minor transplacental passage of fondaparinux in vivo (Letter to the Editor). N Engl J Med 2004; 350: 1914-5.
39. Elalamy I, Lecrubier C, Potevin F, Abdelouahed M, Bara L, Marie JP, Samama M. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin dependent factor of twenty-five patients with heparin associated thrombocytopenia. Thromb Haemost 1995; 74: 1384-5.
40. Amiral J, Lormeau JC, Marfaing-Koka A, Vissac AM, Boyer Neumann C, Tardy B, Herbert M, Meyer D. Absence of cross-reactivity of SR 90107A/ORG 31540 pentasaccharide with antibodies to heparin-PF4 complexes developed on heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8: 114-7.
41. Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, Eichler P, Meuleman D, Petitou M, Herault J-P, Cariou R, Herbert J-M. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105: 139-44.
42. Harenberg J, Jorg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 2004; 89: 1017-8.
43. Bijsterveld NR, Moons AH, Boekholdt SM, Van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-4.
44. Bijsterveld NR, Vink R, Van Arken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004; 124: 653-8.
45. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG, for the Steering Committee of the Pentasaccharide in Hip Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1340-2.
46. Turpie AGG, Bauer K, Eriksson BI, Lassen MR, for the Pentathlon 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-6.
47. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG, for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-20.
48. Bauer KA, Eriksson MD, Lassen MR, Turpie AGG, for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after major elective knee surgery. N Engl J Med 2001; 345: 1305-10.
49. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the Steering Committees of the Pentasaccharide Orthopedic. Prophylaxis studies. Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-40.
50. Eriksson BI, Lassen MR. PENTasaccharide in Hip-FRActure Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicentre, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163: 1733-42.
51. Cohen AT, Gallus AS, Lassen MR, Tomkowski W, Turpie AGG, Davidson BL, Cariou RG, Lensing AWA, Egberts JFM. Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS). J Thromb Haemost 2003; 1: Suppl 1, AbstractP2046.
52. Agnelli G, Bergqvist D, Cohen A, Gallus A, Gent M. A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus Study. J Thromb Haemost 2003; 1: Suppl 1, AbstractOC006.
53. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, MATISSE Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867-73.
54. MATISSE Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-702.
55. Coussement PK, Bassand JP, Convens C, Vrolix M, Boland J, Grollier G, Michels R, Vahanian A, Vanderheyden M, Rupprecht HJ, Van De Werf F. A synthetic factor Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. Eur Heart J 2001; 22: 1716-24.
56. Fergusson JJ. Meeting highlights - American Heart Association scientific sessions 2001. Circulation 2002; 105: e37-41.
57. PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J Thromb Haemost 2004; 2: 47-53.
58. Herbert JM, Bernat A, Dol F, Herault JP, Crepon B, Lormeau JC. DX-9065a, a novel synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J Pharmacol Exper Ther 1996; 276: 1030-8.
59. Murayama N, Tanaka M, Kunitada S, Yumada H, Inoue T, Terada Y, Fujita M, Ikeda Y. Tolerability, pharmacokinetics and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin Pharmacol Ther 1996; 66: 258-64.
60. Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, Lincoff AM, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, Zillman LA, Shimoto Y, Robertson TL, Kunitada S, Armstrong PW. Harrington RA. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 2002; 105: 2385-91.
61. Alexander JH, Dyke CK, Yang H, Becker RC, Hasselblad V, Zillman LA, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff AM, Sain-Jacques H, Chetcuti S, Burton JR, Buergler JM, Spence FP, Shimoto Y, Robertson TL, Kunitada S, Bovill EG, Armstrong PW, Harrington RA, The XaNADU-PCI PILOT Investigators. Initial experience with factor Xa inhibition in percutaneous coronary intervention: the XaNADU-PIC Pilot. J Thromb Haemost 2004; 2: 234-41.
62. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, Razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery. Blood 2003; 102: 15a (Abstract41).
63. Ettingshausen CE, Veldmann A, Beeg T, Schneider W, Jager G, Kreuz W. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thomb Hemost 1999; 25: 537-41.
64. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OD. An open-label study of the adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96: 3719-24.
65. Bernard GR, Vincent JL, Laterre PF, La Rosa SP, Dhainout JR, Lopez-Rodriguez A, Steingrub JS, Garber GE, Heiterbrand JD, Ely EW, Fisher Jr CW Efficacy and safety of recombinant activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
66. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347: 993-1000.
67. Parkinson JF, Grinnell BW, Moore RE, Hoskins J, Vlahos CJ, Bang NU. Stable expression of a secretable deletion mutation of recombinant human thrombomodulin in mammalian cells. J Biol Chem 1990; 265: 12602-10.
68. Gomi K, Zushi M, Honda G, Kawahara S, Matsuzaki O, Karabayashi T, Yamamoto S, Maruyama I, Suzuki K. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood 1990; 75: 1396-9.
69. Aoki Y, Ohishi R, Takei R, Matsuzaki O, Mohri M, Saitoh K, Gomi K, Sugihara T, Kiyoto T, Yamamoto S. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III. Thromb Haemost 1994; 71: 452-5.
70. Kearon C, Comp P, Douketis JD, Royds R, Yamada K, Gent M. A dose-response study of a recombinant human soluble thrombomodulin (ART-123) for prevention of venous thromboembolism after unilateral total hip replacement. J Thromb Haemost 2003; 1: Suppl 1, AbstractOC330.
71. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74.
72. Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost 1995; 74: 1209-74.
73. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
74. Hogg PI, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-23.
75. Weitz J, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998; 97: 544-52.
76. Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 69: 157-63.
77. Stringer KA, Lindenfeld J. Hirudins: antithrombin anticoagulants. Ann Pharmacother 1992; 26: 1535-40.
78. Greinacher A, Volpel H, Janssens LJ, Hach-Wunderle V, Kemkes-Matthes B, Eighler P, Mueller-Velten HG, Potzsch B. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study. Circulation 1999; 99: 73-80.
79. Farner B, Eicher P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001; 85: 950-7.
80. Reiss FC, Lower C, Sellig C. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J Thorac Cardiovasc Surg 1995; 11: 265-7.
81. Potzch B, Iversen S, Reiss FC. Recombinant hirudin as an anticoagulant in open-heart surgery: a case-report. Ann Hematol 1994; 68: A53.
82. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang JK, Rifkin SD, Moran J, Hursting MJ, Kelton JG, ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-43.
83. Lewis BE, Wallis DE, Leya F, Hurstin MJ, Kelton JG, for the Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163: 1849-56.
84. Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: Present and future. Circulation 2002; 105: 1004-11.
85. Bittl JA, Strony J, Brinker J, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutch E, Adelman B, for the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. Am Engl J Med 1995; 333: 764-9.
86. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142: 952-9.
87. Bittl JA. Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators. Am Heart J 1995; 130: 658-65.
88. Kong DF, Topol EJ, Bittl JA, White HD, Theroux P, Hasselblad V, Califf RM. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999; 100: 2049-53.
89. Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, Topol EJ. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002; 143: 847-53.
90. Eincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, De Feyter PJ, Vahanian A, Topol E, REPLACE-2 Investigators. Bivalirudin and provisional GPIIb/IIIa blockade compared with heparin and planned GPIIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial. JAMA 2003; 289: 853-63.
91. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee joint replacement. Thromb Haemost 2003; 89: 288-96.
92. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffman K, Ungell A, Sorensen H, Nagard S, Abrahamsson A, Bylund R. The direct thrombin inhibitor melagatran and its oral prodrug H376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-81.
93. Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, Larsson M, Eriksson UG. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediatged drug-drug interactions. Clin Pharmacokinet 2003; 42: 765-77.
94. Eriksson UG, Johansson S, Attman PO, Mulec H, Frison L, Fager G, Samuelsson O. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin Pharmcokinet 2003; 42: 743-53.
95. Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Eriksson UG. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003; 42: 381-92.
96. Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-7.
97. Heit JA, Colwell DW, Francis CW, Ginsberg JS, Berkowitz SD, Whillple J, Peters G, for the AstraZeneca Arthroplasty Study Group. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. Arch Intern Med 2001; 161: 2215-21.
98. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kalebo P, Panfilow S, Eskilson C, Nylander I, Andersson M, on behalf of the EXPRESS Study Investigators. The oral direct thrombin inhibitor ximelagatran, and its subcutaneous form, melagatran, compared with enoxaparin for prophylaxis of venous thromboembolism in total hip or total knee replacement: the EXPRESS study. Blood 2002a; 100: 299 (Abstract).
99. Colwell CW, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, Neubauer J, Mcelhattan JL, Peters GR, Francis CW. Comparison of ximelagatran, an oral direct thrombin inhibitor with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003b; 1: 2119-30.
100. Colwell C, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, for the EXULT B Investigators. Randomized double-blind comparison of ximelagatran, an oral direct thrombin inhibitor and warfarin to prevent venous thromboembolism (VTE) after total knee replacement. Blood 2003a; 102: 14 (Abstract 39).
101. Francis CS, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiment G, Peters GR, Roth AW, McElhattan J, Colwell CW, for the EXULT A Study Group. Comparison of ximelagatran with warfarin for prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349: 1703-12.
102. Eriksson H, Wahlander K, Gustafsson D, for the THRIVE I Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1: 41-47.
103. Francis CW, Ginsberg JS, Berkowitz SD, Bounamoux H, Davidson BL, Eriksson H, Fiessinger JN, Huismann M, Lundstrom T, Nystrom P, for the THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE Treatment Study. Blood 2003; 102: 6a (Abstract 7).
104. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H, for the THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713-21.
105. Petersen P, Grind M, Adler J. SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding tolerability, and safety study. J Am Coll Cardiol 2003; 41: 1445-51.
106. Peterson P. A long-term follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Blood 2001; 98: 2953 (Abstract).
107. Executive Steering Committee on Behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-8.
108. Halperin JL. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. J Am Coll Cardiol 2005; 45: 1-9.
109. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson NH, Goodvin A, Nystrom P, Bylock A, for the ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003; 362: 789-92.
110. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J Int Med 2003; 254: 322-34.
111. Wienen W, Nar H, Ries UJ. Antithrombotic effects of the direct thrombin inhibitor BIBR953ZW and its orally active prodrug BIBR1048MS in a model of venous thrombosis in rabbits. Thromb Haemost 2001; 86: Abstracts of the XVIII ISTH Congress; AbstractOC583.
112. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P, for the BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103-11.
113. Stangier J, Nehmiz G, Liesenfeld KN, Holzschuh I, Hermansson K, Svaerd R, Dahl OE, Ahnfelt L, Eriksson BI. Pharmacokinetics of BIBR953ZW, the active form of the oral direct thrombin inhibitor dabigatran etexilate, in patients undergoing hip replacement. J Thromb Haemost 2003; 1: AbstractP1916.
114. Stangier J, Liesenfeld KH, Troconiz CH, Tillmann IF, Schaefer HG, Hermansson K, Eriksson BI. The effect of BIBR953ZW, the active form of the oral direct thrombin inhibitor BIBR1048, on the prolongation of the aPTT and ECT in orthopedic patients: a population pharmacodynamic study. J Thromb Haemost 2003; 1: AbstractP1917.
115. Eriksson BI, Dahl OE, Ahnfelt L, Kalebo P, Stangier J, Nehmiz G, Hermansson K, Kohlbrenner V. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate in patients undergoing total hip replacement: BISTRO 1. J Thromb Haemost 2004; 2: 1573-80.
116. Albers GW, Dalen J, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119: 94S-206S.